Congratulations to client NewAmsterdam Pharma Corporation who reported positive topline results from their Phase 3 BROOKLYN study this morning!
JUST IN: Positive topline results from our Phase 3 BROOKLYN study of obicetrapib, our investigational CETP inhibitor, in patients with heterozygous familial hypercholesterolemia (HeFH). https://bit.ly/3LKFu3M